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ABSTRACT 
Multivalent virus binding inhibitors are a promising new class of antivirals, preventing virus 
infection of cells by inhibiting the first step in the viral infection cycle –binding of viruses to the 
cell surface. The design of multivalent virus binding inhibitors is complex as many properties, 
such as inhibitor size and functionalization with virus attachment factors, have a strong impact on 
the inhibition efficiency. In this study, we synthesized virus binding inhibitors, the design of which 
has been inspired by mucins, which are naturally occurring glycosylated proteins with molecular 
weights in the MDa range and which show high affinity in the interaction with various viruses. 
Hyperbranched polyglycerols (hPG), serving as polymeric scaffolds, were functionalized with 
sialic acids and sulfate groups at degrees of functionalization as suggested from the structure of 
mucins. The molecular weights of the hPG-based inhibitors ranged between 10 and 2600 kDa, 
thereby hitting the size of mucins (MDa scale) and allowing for comparing the inhibition efficiency 
of the largest, mucin-sized inhibitor (2600 kDa) with related inhibitors of lower molecular weight. 
Inhibition efficiencies were determined by various methods based on the inhibition of influenza A 
virus (IAV) binding to lipid membranes, including an assay based on total internal reflection 
fluorescence (TIRF) microscopy that allows for probing the interaction of IAV with its native 
attachment factor, sialic acid. Potent inhibition is observed in all assays already at pM 
concentrations for the mucin-sized inhibitor, while decreasing the inhibitor’s molecular weight 
also decreased its inhibition efficiency. In addition, a biphasic binding behavior of the inhibitors 
to IAV is observed, which is attributed to differences in the binding affinity to two IAV envelope 
proteins, neuraminidase and hemagglutinin. 
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Viral infections and resulting pandemics are a human danger and repeatedly get into the focus 
due to the circulation of newly emerging viruses, such as Zika, influenza, and corona viruses.1-3 
The development of antivirals to fight viral infections is often a time-consuming process and the 
generated drugs are often effective only for a certain period of time as mutation of the targeted 
virus may cause the developed antiviral to become ineffective, for example due to occurrence of 
resistance.4 Hence, antivirals targeting highly conserved structures of viruses, such as envelope 
proteins that are involved in virus binding to the membrane of the host cell, are entering more and 
more the focus of current research.5, 6 As virus binding proteins typically show a very weak affinity 
to their native attachment factors on the cell membrane,7 viruses bind to cells by forming many 
protein-receptor interactions in parallel, thereby generating a multivalent interaction to the cell 
membrane.8 This first step in the infection cycle of cells can be inhibited by addition of multivalent 
binding inhibitors.5, 9 Yet the design of such compounds is complicated by the fact that many 
properties, such as inhibitor size and functionalization with virus attachment factors, have a strong 
impact on the inhibition efficiency,10 making the process of finding inhibitor designs with high 
inhibition efficiency a time consuming matter. 
Nevertheless, the concept of using multivalent interactions to hinder binding of infectious agents 
(viruses and bacteria) to cells is implemented in the biological hydrogel mucus, which covers 
almost all epithelia cells.11 It forms the first defense barrier against viruses and bacteria by 
capturing such infectious agents before they are able to reach to the cell surface.12 Mucus is formed 
by dynamic cross-linking of mucins, which are highly glycosylated proteins having molecular 
weights ranging between 0.1 and few MDa and bind with high specificity and selectivity to viruses 
while allowing other species (e.g., nutrients) to pass the hydrogel.11, 13 As mucins are effective 
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binders of various virus species, our study aims to develop a virus binding inhibitor that is inspired 
by the design of mucins, allowing for potent and potentially broad band inhibition of virus binding.  
In particular, we aim to generate a polymer-based multivalent virus binding inhibitor with a 
molecular weight hitting the million Dalton (MDa) scale, which is a value being in the middle of 
the weight range reported for mucins.13 Besides mimicking the large size of mucins, such large 
values are also motivated by the observation that the size of a binding inhibitor has a strong impact 
on its efficiency to bind to viruses,10 which led to the suggestion that the optimal size of a virus 
binding inhibitor is ~ one third of the size of the virus to be inhibited. As many viruses are within 
the size range of 30 – 200 nm, the size of the virus inhibitor should therefore be on the order of a 
few tens of nanometers, suggesting to use polymer scaffolds having a molecular weight hitting the 
MDa scale. Besides size, the functionalization of the inhibitor is also known to be an important 
determinant for the virus-inhibitor interaction strength. Mucins present a high amount of terminal 
sialic acid and sulfate moieties,12 which are known to play a role in the binding of various viruses, 
motivating to functionalize the virus binding inhibitor with sialic acid and sulfate groups (at 
degrees of functionalization comparable to mucins) to ensure efficient binding to viruses and offer 
the perspective to act as a broad band virus binding inhibitor. The performance of the synthesized, 
mucin-inspired virus binding (MuVib) inhibitor is investigated by probing the binding inhibition 
of influenza A virus (IAV) strain X31 (H3N2) using various assay and by comparing its inhibition 
efficiency to the one of hPG inhibitors having the same functionalization but lower molecular 
weight.  
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RESULTS AND DISCUSSION 
In order to generate a high molecular weight, polymer-based, multivalent virus binding inhibitor, 
hyperbranched polyglycerols (hPG) are promising scaffolds in the design of such inhibitors, as 
hPGs have been shown to be highly biocompatible and as the synthesis of hPGs with molecular 
weights of several 100 kDa has recently been demonstrated, making an successful extension into 
the MDa range highly likely.14, 15 The strategy for the synthesis of a MDa-sized hyperbranched 
polyglycerol (hPG) scaffold for use as mucin-inspired virus binding (MuVib) inhibitor is shown 
in Figure 1a. In addition to this MuVib inhibitor, hPG scaffolds with molecular weights ranging 
between 10 kDa and 500 kDa have been synthesized, which allows for investigating the effect of 
the inhibitor size on the inhibitor efficiency as suggested in a recent work by Vonnemann et al.10 
While hPGs up to 600 kDa can be synthesized in a single step,16 the synthesis of the 2600 kDa 
hPG required an additional step, in which 600 kDa hPGs served as macroinitiator for a further 
polymerization (Figure 1a) to generate a mucin-sized polymer.15 This approach yielded 4 different 
hPG scaffolds with molecular weights of 10 kDa, 100 kDa, 500 kDa and 2600 kDa (Table 1), 
exhibiting hydrodynamic diameter of approximately 6 nm (10 kDa), 9 nm (100 kDa), 13 nm (500 
kDa) and 29 nm (2600 kDa), respectively.  
Besides size, the functionalization of a polymer scaffold surface with chemical groups is also an 
important parameter for its efficiency to serve as virus inhibitor, as it determines the amount and 
strength of interactions formed between a virus and the inhibitor.7 Many terminal glycans in 
mucins terminate with a sialic acid (SA) or sulfate group.13 Furthermore, both chemical groups are 
known attachment factors for various viruses:17 SAs are, for example, involved in the attachment 
of influenza virus and many corona virus strains,18, 19 while viruses such as the vesicular stromatitis 
virus or herpes simplex virus bind to sulfated glycosaminoglycans.20, 21 As these two chemical 
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groups already enable interaction with various virus species, we simplified the complex structure 
of mucins by regarding only these two terminal functional groups and thus by functionalizing the 
hPG scaffolds with SAs and sulfate residues as shown in Figure 1b. Various values for the content 
of SA and sulfate groups in mucins have been reported in the literature, typically ranging between 
4 -20 wt.% for sialic acid and 1.2 – 11.9 wt.% for sulfates.22, 23 In this study, 5 mol% of the 
hydroxyl groups were substituted with SA and sulfate moieties (Figure 1b), which resulted in 
15 wt.% SA and 5 wt.% sulfate (Table 1), being close to the middle of the ranges reported for 
mucins. In addition, two control polymers were prepared, carrying only one of the two moieties.  
All functionalized inhibitors show a negative zeta potential ranging from -22 to -27 mV (Table 1), 
which is caused by the incorporation the negatively charged sulfate and SA moieties. Both, 
unfunctionalized and functionalized hPG polymers are highly water soluble. 
In a next step, we assessed the applicability of the synthesized inhibitors to hinder virus binding 
to cell membranes. These investigations are done by probing the inhibition of influenza A viruses 
(IAVs; strain X31), being a highly important representative of the viruses that are known to bind 
to SA or sulfate moieties. Two membrane proteins of IAV are involved in its binding to cell 
membranes, hemagglutinin (HA) and neuraminidase (NA). Both proteins are able to interact with 
SAs, but while HA is known to promote IAV attachment to the cell membrane, NA is known to 
possess SA cleavage activity and is thus believed to promote IAV egress (after the virus replication 
cycle has been completed).24-26 According to Harris et al.27 there are approximately 300 HA 
compared to 50 NA in the membrane of the influenza A virus strain X31. Recently, more evidence 
is accumulating that NA also contributes to the binding of IAV to the membrane.28, 29 The interplay 
between HA and NA is important to pass the whole virus life cycle and gets more and more in the 
focus of many studies.30 To prevent NA-mediated cleavage of SA at our synthesized binding 
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inhibitor, a thioether bond was used to link the sialic acid to the polymer scaffold. This thioether 
bond cannot be enzymatically cleaved by NA. Naturally occurring SAs in mucins are O-
glycosylated and can be cleaved by NA. 
Initially, the inhibitor performance was investigated using the well-established hemagglutination 
inhibiton assay (Figure S12),29 which takes advantage of the feature that red blood cells become 
crosslinked upon interaction with IAVs (called hemagglutination).29 By the addition of virus 
binding inhibitors, the interaction between the virus and the red blood cells can be inhibited and 
the lowest inhibitor concentration at which no agglutination occurs anymore is defined as 
inhibition constant ki. The ki of the 10 and 100 kDa inhibitors are in the low µM range, whereas 
the 500 kDa inhibitor is in the nM range (Table 2). The most potent inhibition was exhibited by 
the 2600 kDa MuVib inhibitor (31 pM; 0.1 µg/mL), irrespective if this hPG was functionalized 
with SA and SO4 or SA alone. Sulphated hPGs showed no inhibition. 
In order to further probe how the IAV-SA interaction is affected by the addition of the hPG-
based inhibitors, we employed a recently introduced virus-membrane binding assay based on total 
internal reflection fluorescence (TIRF) microscopy (Figure 2).31 In this assay, a supported lipid 
bilayer (SLB), which is supplemented with the attachment factor of the virus of interest, is formed 
at a glass interface and the (transient) binding of fluorescently labeled viruses to the SLB is 
monitored using TIRF microscopy (Figure 2a). By choosing TIRF illumination, the excitation light 
hits the SLB-glass interface at the critical angle of total internal reflection, which generates an 
evanescent wave with a penetration depth of ~ 100 – 150 nm,32 so that fluorescence is only excited 
in very close vicinity of the SLB. Hence, to resolve fluorescently labeled viruses for an appreciable 
time period in TIRF microscopy, they have to be bound to the SLB, while unbound viruses are not 
visible.  
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For probing the IAV-SA interaction, a SLB based of POPC (96.2 wt.%, 1-palmitoyl-2-oleoyl-
glycero-3-phosphocholine ) and DSPE-PEG2k (3.8 wt.%, 1 mol%, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (sodium salt)) was supplemented 
with the ganglioside GD1a (2.5 wt.%, 1 mol%), which provides the native IAV attachment factor 
sialic acid for the interaction studies. IAVs have been labeled with the dye rhodamine octadecyl 
and TIRF microscopy was used to monitor IAV attachment to and IAV release from the SA-
containing SLBs (Figure 2a). Single particle tracking (SPT) applied to the resulting TIRF 
microscopy videos allowed for tracking the motion of single viruses interacting with the SLB with 
high spatial accuracy (< 15 nm) and subsequent application of the equilibrium fluctuation analysis 
(EFA)33, 34 yielded information on the rate of IAV attachment to the SLB, the IAV diffusion 
coefficient, and residence time distribution as described previously.31 
As the inhibitors are designed to prevent IAV binding to membranes, it is straightforward to 
assess their inhibition efficiency by quantifying the change of the rate of IAV attachment to the 
SLB as function of the inhibitor concentration (Figure 2b). According to the EFA procedure,33, 34 
this rate is extracted by calculating, for each recorded TIRF movie separately, the total number of 
IAVs that have been newly bound to the SLB since the beginning of the TIRF movie. Under 
equilibrium conditions (i.e., if SLB-bound and solution-dissolved viruses are in thermodynamic 
equilibrium) this number, the so-called cumulative number of newly arising viruses, increases 
linearly with measurement time, and the slope of this function corresponds to the IAV attachment 
rate for the area probed.33, 34 Addition of the inhibitors changed the slope of the cumulative number 
of newly arising IAVs, indicating a change of the rate of IAV attachment to the SLB that is caused 
by addition of inhibitors (Figure 2b). As the efficiency in inhibiting virus binding can be extracted 
from the change in the IAV attachment rate upon inhibitor addition,21 in the following the relative 
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on-rate will be given, which was calculated by normalizing the attachment rates by the value 
measured in absence of any inhibitor. 
All functionalized hPG inhibitors showed a decrease in the relative on-rate for a sufficiently 
large inhibitor concentration (Figure 3). Fitting a Langmuir-type inhibition curve to the relative 
on-rate in this concentration range allows for determining the inhibitor concentration, at which the 
IAV binding rate to the SLB has been reduced by 50 %, the so-called IC50 value (Table 2). While 
the 10 to 500 kDa hPG inhibitors showed IC50 values in the µM molar range, the 2600 kDa hPG 
inhibitors reached pM values. This impressive value is not only due to high molecular weight of 
these large inhibitors, but by an improved inhibition potential, as indicated when comparing the 
IC50 values expressed in mass concentrations (Table 2): Compared to the smaller inhibitors a virus 
inhibition is achieved for the 2600 kDa hPGs at a three order of magnitudes lower mass 
concentration, which is indicative for a multivalency-based enhancement of the inhibition. In 
addition, both SA-functionalized 2600 kDa hPGs showed comparable inhibition efficiency, i.e., 
hPGs with SA and sulfate functionalization is not notably more effective than the inhibitor with 
just SA, while the one lacking SA but carrying sulfates did not show any IAV inhibition, as 
expected for this negative control. Unexpectedly, the non-functionalized MDa hPG also showed 
IAV binding inhibition with an IC50 value of ~1000 pM. We attribute this behavior to the slightly 
positive zeta potential (Table S1 in SI) of this polymer, which promotes its binding to negatively 
charged sialic acid groups present in the SLB and thus blocks the interaction between IAVs and 
the SLB. This view is confirmed by the lack of any inhibition potential of hPG2600-SO4, which 
possesses, as all functionalized hPGs, a negative surface charge and is therefore not able to bind 
to the SLB. A direct interaction of the unfunctionalized polymer (hPG2600) with the virus is 
unlikely, which is supported by the lack of any activity of hPG2600 in the HAI assay. A reason for 
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its positive zeta potential could be the incorporation of salt ions although the polymer was 
excessively dialyzed against water. A treatment of the polymer solution with cation exchanger 
before the measurement of the zeta potential did not change the slightly positive zeta potential 
result. All functionalized hPGs show an expected zeta potential, which verifies the measurement 
principle.  
Furthermore, the results on the IAV binding inhibition obtained using the HAI- or TIRF-based 
assays are qualitatively in good agreement (Table 2), although the TIRF-based assay reports in 
general slightly smaller IC50 values than the HAI-assay. Nevertheless, both assay show that the 
IC50 values generally decrease with increasing inhibitor size, i.e., that the inhibitors become more 
potent for increasing size of it scaffold. This trend is in fact expected based on the theoretical 
considerations of Vonnemann et al.,10 who show that the optimal size of a virus binding inhibitor 
is approximately one third of the size of the virus to be inhibited. As IAV X31 typically shows 
spatial extensions ranging between 80 and 120 nm, an optimum in binding inhibition is expected 
for inhibitor diameters on the order of 30 nm, which is realized by the MuVib inhibitor (hPG2600-
SA-SO4, Table 1). In this context, the decrease of the IC50 with increasing inhibitor size 
qualitatively matches to the predictions of Vonnemann et al.10 A test, if the MuVib inhibitor indeed 
achieves optimum inhibition efficiencies was, however, not possible, as this would have required 
to synthesize notably larger hPG scaffolds, which was not achievable in this study. 
Nevertheless, while the HAI assay provides a rather binary readout (i.e., if the inhibitor 
concentration is sufficient to inhibit agglutination of red blood cells),29 the changes in the IAV 
attachment rate measure by TIRF showed in fact a continuous and biphasic progression: Starting 
at small inhibitor concentrations (<< IC50), the attachment rates first increased with increasing 
inhibitor concentration, followed by a saturation and a strong decrease as large inhibitor 
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concentrations (~ IC50). This surprising behavior indicates that the SA-functionalized hPG 
inhibitors actually promote IAV attachment at relatively low inhibitor concentrations, while IAV 
binding inhibition is observed for sufficiently large inhibitor concentrations. The first phase 
(increase in IAV attachment rate) is not resolvable in the HAI-assay, as the IAV concentration is 
chosen such that agglutination is observed in absence of the inhibitor. This means that an increase 
in the IAV attachment rate to the cell membranes is not resolved by HAI, as in absence of inhibitors 
the IAV attachment rate is already sufficiently large to achieve agglutination. 
This biphasic behavior upon addition of inhibitors, which was observed for all inhibitors except 
for hPG100-SA-SO4 and which first increases the IAV binding rate to membranes at low inhibitor 
concentrations until a decrease is observed at large concentrations, was unexpected. Nevertheless, 
the increase of the rate of IAV attachment upon inhibitor addition resembles changes to the IAV 
binding properties observed upon application of neuraminidase inhibitors.31 Hence, the biphasic 
behavior suggests that at relatively low concentrations the inhibitors bind first to the NA and 
therefore act as NA inhibitors, while binding to HA and thus binding inhibition requires higher 
inhibitor concentrations. This interpretation is consistent with measurements on the affinity of the 
envelope proteins to sialosides,35, 36 showing that the dissociation constant KD of the NA-SA 
interaction is 3 order of magnitude smaller than the one of the HA-SA interaction (~ µM versus ~ 
mM, respectively) and supporting the hypothesis that also the inhibitors exhibit higher affinity 
(lower KD value) towards NA than HA. 
If the hypothesis is correct that the inhibitors bind preferentially to NA at relatively low inhibitor 
concentrations and to HA at sufficiently large ones, one would expect to see inhibitor 
concentration-dependent changes of the IAV off-rate and valency distribution, as both IAV 
binding properties strongly depend on the functional balance between HA and NA.31 In order to 
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test this hypothesis, we extracted the off-rate and valency distributions as recently described for 
monovalent inhibitors.31 In brief, here we make use of the fact that the diffusion coefficient of 
SLB-bound IAVs, D, decreases with increasing valency (= number of bound GD1a gangliosides), 
so that the changes of the IAV valency distribution also induce change the distribution of IAV 
diffusion coefficients. Although the exact relationship connecting IAV valency and diffusion 
coefficient has not yet been resolved, all theoretical models imply that both properties are 
connected by a monotonously decreasing function, i.e., large values of the diffusion coefficient 
correspond to a small value of the average valency and vice versa.37 Furthermore, the measurement 
of the IAV diffusion coefficient also allows to deconvolute the IAV residence time distribution 
from valency effects, yielding valency-resolved off-rate distributions.31 
In absence of any inhibitor (open circles, Figure 4a), the observed off-rate distribution is 
dominated by a decrease for increasing apparent average valency 1/D, but also shows a peak 
structure, leading to elevated off-rates at intermediate average valencies (1/D ~ 8 s/µm²). This 
finding matches to previous observations,31 in which it is shown that this peak structure is caused 
by the opposing functionalities of HA and NA and vanishes upon application of NA inhibitors 
such as zanamivir. Furthermore, the addition of zanamivir also increased the rate of IAV 
attachment and both effects together yielded a strong increase in the number of bound IAVs. 
Interestingly, exactly the same behavior is observed here at relatively low inhibitor concentrations, 
at which the relative IAV on-rate increases (Figure 3) and the IAV off-rate decreases with 
increasing inhibitor concentration (open triangles and squares, Figure 4a). Hence, at relatively low 
concentrations, the inhibitors behave like a NA inhibitor with respect to the induced changes in 
IAV attachment and off-rate distribution. Additional evidence is provided by the diffusion 
coefficient distributions (Figure 4b), which showed a shift from large to small values (indicating 
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an increase in average binding valency; “NA-like inhibition”) upon addition of small amounts of 
the inhibitor (<< IC50) and a shift from small to large diffusion coefficient values (indicating an 
decrease in average binding valency; “HA inhibition”) upon addition of small amounts of the 
inhibitor (>> IC50).  
Furthermore, the phenomenon of the increased IAV attachment at small inhibitor concentrations 
(<< IC50) was further investigated by binding tests to MDCK-II cells. Here, labelled IAVs were 
mixed with different concentration of the inhibitor hPG2600-SA-SO4 at room temperature for 
45 min. Afterwards, the virus-inhibitor mixture was incubated with MDCK-II cells for 2 h on ice. 
Non-bound IAVs were removed by washing twice with PBS buffer, while bound IAVs remained 
at the cell surface. Using confocal laser scanning microscopy Z-wide images of the cell layer were 
taken and stacked to visualize all viruses at the cell surface, followed by quantifying the number 
of bound viruses using ImageJ.38 The number of MDCK-II cell-bound IAVs (Figure 5) showed 
the same dependence of the inhibitor concentration as the relative on-rate determined using TIRF 
microscopy (Figure 3), verifying an increased IAV attachment at low concentrations and a 
decrease in IAV attachment at higher concentrations. The sulfated derivative (hPG2600-SO4, 10 
nM) was used as negative control and shows the same number of attached viruses as the lowest 
concentration (10-4 pM) of hPG2600-SA-SO4. Hence, the biphasic change in the IAV binding 
behavior upon inhibitor addition is observed for IAVs interacting with attachment factor-equipped 
SLBs and with cell membranes, which further supports our view that these inhibitors behave as 
NA-like inhibitors at low inhibitor concentrations and as HA inhibitors at high concentrations. 
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CONCLUSIONS 
In this study, new hyperbranched polyglycerol (hPG)-based virus binding inhibitors have been 
synthesized, the functionalization of which (sialic acids and sulfate groups) have been inspired 
from mucins. The molecular weights of the synthesized inhibitors covers the range between 10 
and 2600 kDa, thereby hitting the size of mucins (MDa scale) and allowing for comparing the 
inhibition efficiency of the mucin-inspired virus binding (MuVib) inhibitor (2600 kDa molecular 
weight) with related inhibitors of lower molecular weight. The efficiency of the synthesized 
compounds to inhibit the binding of a common respiratory virus, a H3N2 influenza A virus (IAV), 
was assessed using a cell binding and the hemagglutination inhibition assay, both of which provide 
information about the minimum inhibitor concentration that needed to inhibit IAV binding to 
membranes. Furthermore, a recently developed TIRF-based assay was employed to quantify, how 
inhibitor addition modified the multivalent interaction arising between IAVs and their native 
attachment factor, sialic acids. Surprisingly, the IAV binding to membranes showed a biphasic 
behavior for increasing inhibitor concentrations: At relatively low inhibitor concentrations, the 
IAV binding first increased with increasing inhibitor concentrations, followed by a second regime 
at higher inhibitor concentrations, at which the expected decrease in IAV binding was observed 
for increasing inhibitor concentrations. The results of the TIRF-based assay and the cell binding 
assay indicate that the inhibitors binds at low inhibitor concentrations preferentially to the IAV 
envelope protein neuraminidase (NA), leading to an enhancement of the IAV binding to lipid 
membranes, while at larger inhibitor concentrations, it binds additionally to another IAV envelope 
protein, hemagglutinin (HA), causing IAV binding inhibition. Potent inhibition of IAV binding 
(HA inhibition) is observed in all these assays already at pM concentrations for the MuVib 
inhibitor (2600 kDa molecular weight), while decreasing the molecular weight of the inhibitors 
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decreased their inhibition efficiency (increase in their IC50 value), which is in qualitative 
agreement with the prediction by a recent study of Vonnemann et al.10 
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Figure S12 gives an example for the HAI assay. Furthermore, the properties of the hPG scaffolds 
and inhibitors are summarized in Table S1 and S2, respectively. (PDF) 
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MATERIALS AND METHODS 
Synthesis of high-molecular weight (MDa) hPG – The synthesis of the MDa hPG was 
perfomed in two steps.15 First, a macroinitiator was synthesized in a heterogenous reaction mixture 
in dioxane. Dry trimethylolpropane (120 mg, 0.89 mmol, 1.0 eq.) was partially deprotonated (30 
% OH) with potassium methoxide (67 µL, 0.27 mmol, 0.3 eq., 25 % in methanol) in argon 
atmosphere at 60 °C for 30 min. After the addition of 24 mL dioxane (dry) the turbid mixture was 
heated to 100 °C. Glycidol (12 mL, 0.18 mol, 201 eq.) was slowly added (0.5 ml/h) via syringe 
pump into the reaction mixture. The polymer was purified by removing the dioxane, precipitation 
as methanolic solution in acetone and dialysis against water in regenerated cellulose membrane 
(10 kDa MWCO). The resulted hPG (Mn: 600 kDa, Đ 1.1) was obtained with a yield of 93.6 %. 
This hPG was used as macroinitiator to grow the polymer further. 2.5 g (0.034 mol, total OH 
groups) of the lyophilized polymer was dissolved in dry DMF (35 mL). The polymer was partially 
deprotonated with the addition of potassium hydride in oil (30 wt.%) (80 µg, 272 µL, 2.0 µmol). 
The temperature was increased to 100 °C and glycidol (25 mL, 0.37 mol) were added with a rate 
of 0.9 mL/h. After precipitation in acetone and dialysis against water in regenerated cellulose 
membrane (50 kDa MWCO) the resulted molecular weight was 2.6 MDa with a Đ of 1.4. 
Mesylation and azidation – Both reactions were performed sequentialy in one pot. 1300 mg 
hPG (2.6 MDa) (0.88 mol OH to be functionalized) was dissolved in dry DMF (18 mL). The 
mesylation was done with methanesulfonyl chloride (201 mg, 1.8mmol, 2.0 eq.) in the present of 
triethyl amine (306 µL, 2.2 mmol, 2.5 mol eq.) at room temperature for 16 h. Afterwards the 
azidation was directly performed by the addition of sodium azide (456 mg, 7.0 mmol, 8 eq.) at 80 
°C for 20 h under argon atmosphere. Purification was done by dialysis against water (2 kDa 
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MWCO, benzoylated). The product was analyzed by 1H NMR and elementary analysis to 
determine the amount of introduced azide groups (see Figure S2 in SI). 
Sulfation – The azidated hPG (400 mg, 0.27 mmol OH to be functionalized, 1.0 eq.) was sulfated 
using sulfur trioxide pyridine complex (55.9 mg, 0.4 mmol, 1.3 eq.) in dry DMF (12 mL) at 60 °C 
for 20 h under argon atmosphere. After the reaction time was over the pH value was increased to 
pH 10 by the addition of sodium hydroxide solution (0.3 mol/L). The product was dialyzed against 
sodium hydroxide solution (0.3 mol/L), 10 wt. % NaCl and water. The yield of the sulfation was 
analyzed by elementary analysis. Further, a 1H NMR of the product was performed (see Figure S3 
in SI). 
Click protected propagylated sialic acid by CuAAC – The sulfated polymer hPG2600-N3-SO4 
(150 mg, 0.11 mmol OH to be functionalized, 1.0 eq.) was mixed with acetyl protected 
propagylated sialic acid (72.9 mg, 1.3 mmol, 1.2 eq.) in DMF. Copper sulfate pentahydrate 
(11.1 mg, 0.04mmol, 0.4 eq.) and sodium-L- ascorbate (88.3 mg, 0.4 mmol, 4 eq.) were dissolved 
separately in a small amount of water and combined afterwards. The solution was transferred to 
the polymer solution. The reaction was performed at 50 °C for 20 h under argon atmosphere. 
Complete conversion was verified by the disappearance of the azide band (2100 cm-1) with 
infrared spectroscopy (see Figure S4 in SI). The pH value was increased to pH 10 with sodium 
hydroxide solution (2 mol/L) to cleave the acetyl protection of the sialic acid within 2 h. EDTA 
disodium salt (14.0 mg, 0.04 mmol, 0.4 eq.) was added to improve the removal of copper ions 
during dialysis against water. The purified polymer was analyzed by 1H NMR (see Figure S6 in 
SI) and elementary analysis.  
The synthesized virus binding inhibitors were characterized in regard to size with dynamic light 
scattering (DLS) and in respect of surface charge by zeta potential measurements.  
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DLS - The hydrodynamic diameter was measured by dynamic light scattering at a concentration 
of 1 mg/mL in PBS buffer using Zetasizer Nano series (λ = 532 nm) from Malvern Panalytical 
(Kassel, Germany). Disposable cuvettes (ZEN0040) from Brand (Wertheim, Germany) out of 
polystyrene were used. Before the measurement all samples were filtered through a 0.2 µm 
Minisart RC 15 syringe filter from Satorius (Göttingen, Germany). Temperature equilibration was 
done for 1 min at 25 °C. The measurements were performed for 10 scans each 15 s in back 
scattering mode (173 °). The stated values result from at least 3 measurements. 
Zeta-potential - The surface charge was investigated by zeta-potential measurement with 
Zetasizer Nano series (λ = 532 nm) using folded capillary zeta cells (DTS 1070) from Malvern 
Panalytical (Kassel, Germany). The sample concentration was 1 mg/mL in 10 mM phosphate 
buffer solution (0.411 g/L NA2HPO4, 0.178 g/mL KH2PO4, pH 7.4). All samples were filtered 
through a 0.2 µm Minisart RC 15 syringe filter from Satorius (Göttingen, Germany). 5 
measurements with 10 scans (each 15 s) were done to obtain the zeta potential based on the 
Smoluchowski model.  
The virus binding performance was investigated by two independent methods: hemagglutination 
inhibition (HAI) assay and total internal reflection fluorescence (TIRF) microscopy. 
Hemagglutination inhibition (HAI) assay – The inhibitors were two-fold diluted with PBS in 
a v-shaped microtiter plate. Afterwards, 2 HA X31 virus were transferred to each inhibitor dilution. 
After 30 min incubation time at room temperature 50 µL of 1 % red blood cell solution (Robert 
Koch-Institute, Berlin) was added to each well. Then, it was incubated for 60 min at room 
temperature before the read out was done. The lowest concentration where the sedimentation of 
red blood cells was still inhibited by hemagglutination represents the inhibitor constant ki. 
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Total internal reflection fluorescent (TIRF) microscopy – Single virus tracking was done on 
a supported lipid bilayer (SLB), which represents the cell surface. IAV bind in a multivalent 
fashion to incorporated GD1a gangliosides (1 mol %). Extruded vesicles out of POPC and 1 mol% 
GD1a were exposed in an aqueous solution (0.33 mg/mL) on a cleaned glass, absorb, deform and 
form a cohesive supported lipid bilayer by rupturing on the glass surface. Sialic acids on the GD1a 
are the natural target of IAVs. After 10 min excess vesicles were removed by washing with PBS 
buffer. Then, IAV solution with or without containing binding inhibitor was injected. Through 
excitation in TIRF mode, an evanescent light beam (white light + m-cherry filter) penetrates 
approximately 100 nm in the solution and reaches therefore just bound viruses (~ 100 nm) on the 
membrane. This ensures that rhodamine (R18) labeled viruses in the evanescent region get excited 
and emit light, non-bound labeled virus in the solution are not visible. Videos with 0.11 fps were 
taken to visualize the virus attachment, diffusion and detachment on the GD1a receptor containing 
SLB. The videos are analyzed by homemade MATLAB scripts using equilibrium fluctuation 
analysis (EFA). 
IAV binding to MDCK-II cells – The cultured MDCK II cells are seeded in 8-well confocal 
slides and cultured for 1-2 days till confluency. 100 µL X31 solution (protein content: 0.36mg/mL, 
1.1 × 1011 particles/mL) was incubated with 2µL of 20µM DiO (in ethanol, D4929 in Merck, 
Darmstadt, Germany) for 30 min in dark. The free dyes were removed by spin column then. A 
mixture of 90 µL inhibitor (in PBS) and 10 µL labelled virus was added after 45 min at room 
temperature on the cell layer (culture medium was removed before by washing with PBS twice). 
After an incubation for 2 h on ice, non-binding viruses were removed by washing twice with PBS. 
The cell nucleus was labelled with Hoechst 23358 and the cells fixed with 4% paraformaldehyde. 
Finally, Z-wide images were taken with confocal laser scanning microscopy from the whole cell 
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layer (30 images, step size 0.4 µm). The number of binding viruses was determined from the 
stacked images using ImageJ. 
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Figure 1. Syntheses of mucin-inspired virus binding (MuVib) inhibitor based on high molecular 
weight hPG. Polymerization of the MDa hPG in two steps (a), potassium methoxide in dry 1,4 
dioxane at 95 °C and glycidol addition (0.5 mL/h) (i), potassium hydride in dry DMF at 95 °C and 
glycidol addition (0.9 mL/h) (ii). Functionalization of the MDa hPG, all reactions were carried out 
in dry DMF under argon atmosphere (b), mesylation with mesyl chloride and triethylamine at room 
temperature for 20 h (iii), azidation using sodium azide at 80 °C for 20 h (iv), sulfation with sulfur 
trioxide pyridine complex at 60 °C for 20 h (v), copper-catalyzed alkyne-azide cycloaddition using 
copper sulfate pentahydrate, sodium ascorbate at 50 °C for 20 h (vi), deprotection with sodium 
hydroxide at room temperature for 2h (vii).  
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Figure 2. Experimental setup used to study IAV X31 binding to sialic acids (SAs) and the 
modification of this interaction upon addition of hPG inhibitors. (a) Supported lipid bilayers 
(SLBs) containing the sialic acid-presenting ganglioside GD1a were used as artificial cell 
membranes. Fluorescently labeled IAVs (R18 dye incorporated in the virus envelope) bind to sialic 
acids exposed by the SLB, a process which is followed by TIRF imaging (always performed at 
room temperature; 20 °C). (b) The cumulative number of newly arriving IAVs, as calculated using 
the EFA procedure, increases linearly with time. The slope of these traces is proportional to the 
rate of IAV attachment to the SA-containing SLB and allows for determining IAV binding 
inhibition upon addition of hPG inhibitors. The plot shows a representative example using the 
inhibitor hPG10-SA-SO4.  
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Figure 3. Change in IAV attachment rates upon hPG inhibitor addition. Shown is the relative on-
rate, which was calculated by normalizing the IAV attachment rate at a given hPG inhibitor 
concentration by the IAV attachment rate in absence of the inhibitor. Linear solid lines are to guide 
the eye; sigmoidal solid lines are fits of a Langmuir-type inhibition model to the data. Symbols 
indicate average values ± standard deviation of at least 5 measurements. 
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Figure 4. Changes of the IAV off-rate (a) and diffusion coefficient distribution (b) upon addition 
of the MuVib (hPG2600-SA-SO4) inhibitor. The biphasic binding behavior is also observed in these 
distribution, as addition of small amounts of the inhibitor (≤ 20 pM) leads to a decrease in the off-
rate distribution and a shift of the diffusion coefficient distribution from large to small values 
(indicating an increase in average binding valency), while addition of larger amounts of the 
inhibitor (> 20 pM) restores the off-rate distribution and shifts the diffusion coefficient distribution 
from small to large values (indicating an decrease in average binding valency). 
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Figure 5. Inhibition of IAV X31 binding to MDCK II cells upon addition of the MuVib inhibitor 
(hPG2600-SA-SO4, green symbols) and of the negative control hPG2600-SO4 applied at a high 
concentration (yellow symbol). The cellular assay shows the same biphasic change of IAV binding 
behavior as observed in the TIRF-based binding assay. IAV were labeled with DiO (green 
structures in the cell images), while the MDCK II cells were labeled using Hoechst 23358 (blue 
structures). Symbols indicate average values ± standard deviation of 4 measurements. 
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Table 1. Properties of synthesized virus binding inhibitors based on hPG.  
 da ζ-pot.b SO4c SAc nsulfated nSAd 
 [nm] [mV] [mol%] [wt.%] [mol%] [wt.%] [-] [-] 
hPG10-SA-SO4 4.9 ± 4.2 -26.3 ± 0.9 7.2 6.2 7.0 19.3 7 7 
hPG100-SA-SO4 12.0 ± 7.2 -22.4 ± 1.0 5.0 4.7 5.5 16.5 68 75 
hPG500-SA-SO4 16.3 ± 9.7 -24.3 ± 0.8 3.9 3.7 5.7 17.1 268 392 
hPG2600-SA-SO4 28.1 ± 17.1 -26.8 ± 1.1 5.0 4.7 5.6 16.7 1724 1931 
hPG2600-SA 29.2 ± 15.3 -23.4 ± 0.5 - - 5.6 17.7 - 1931 
hPG2600-SO4 20.8 ± 11.4 -17.1 ± 0.9 4.3 5.3 - - 1482 - 
hPG2600 28.9 ± 14.9 9.5 ± 0.5 - - - - - - 
a) Hydrodynamic diameter obtained by DLS 1 mg/mL in PBS; b) Zeta-potential measurement 
in 10 mM phosphate buffer (pH 7.4); c) amount of converted hydroxyl groups in percent, 
determined by elementary analysis, degree of sialic acid based on fully conversion of azide 
moieties; d) calculated number of sialic acid and sulfate per polymer based on Mn. 
 
Table 2. Inhibitor performance in comparison of HAI and TIRF measurements 
 HAI ki TIRF IC50 
 [mol/L] [µg/mL] [mol/L] [µg/mL] 
hPG10-SA-SO4 82 x 10-6 1214 2 x 10-6 30 
hPG100-SA-SO4 5 x 10-6 685 0.6 x 10-6 82 
hPG500-SA-SO4 50 x 10-9 35 0.4 x 10-6 279 
hPG2600-SA-SO4 31 x 10-12 0.1 30 x 10-12 0.1 
hPG2600-SA 31 x 10-12 0.1 3 x 10-12 0.01 
hPG2600-SO4 no inh. no inh. no inh. no inh. 
 
  
